1. Home
  2. UPB vs GPAT Comparison

UPB vs GPAT Comparison

Compare UPB & GPAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPB
  • GPAT
  • Stock Information
  • Founded
  • UPB 2021
  • GPAT 2020
  • Country
  • UPB United States
  • GPAT United States
  • Employees
  • UPB N/A
  • GPAT N/A
  • Industry
  • UPB
  • GPAT
  • Sector
  • UPB
  • GPAT
  • Exchange
  • UPB NYSE
  • GPAT NYSE
  • Market Cap
  • UPB 521.3M
  • GPAT 379.9M
  • IPO Year
  • UPB 2024
  • GPAT 2024
  • Fundamental
  • Price
  • UPB $11.20
  • GPAT N/A
  • Analyst Decision
  • UPB Strong Buy
  • GPAT
  • Analyst Count
  • UPB 4
  • GPAT 0
  • Target Price
  • UPB $56.50
  • GPAT N/A
  • AVG Volume (30 Days)
  • UPB 500.3K
  • GPAT 74.4K
  • Earning Date
  • UPB 08-14-2025
  • GPAT 01-01-0001
  • Dividend Yield
  • UPB N/A
  • GPAT N/A
  • EPS Growth
  • UPB N/A
  • GPAT N/A
  • EPS
  • UPB N/A
  • GPAT 0.36
  • Revenue
  • UPB $2,296,000.00
  • GPAT N/A
  • Revenue This Year
  • UPB N/A
  • GPAT N/A
  • Revenue Next Year
  • UPB N/A
  • GPAT N/A
  • P/E Ratio
  • UPB N/A
  • GPAT $29.48
  • Revenue Growth
  • UPB N/A
  • GPAT N/A
  • 52 Week Low
  • UPB $5.14
  • GPAT $9.98
  • 52 Week High
  • UPB $29.46
  • GPAT $10.64
  • Technical
  • Relative Strength Index (RSI)
  • UPB N/A
  • GPAT N/A
  • Support Level
  • UPB N/A
  • GPAT N/A
  • Resistance Level
  • UPB N/A
  • GPAT N/A
  • Average True Range (ATR)
  • UPB 0.00
  • GPAT 0.00
  • MACD
  • UPB 0.00
  • GPAT 0.00
  • Stochastic Oscillator
  • UPB 0.00
  • GPAT 0.00

About UPB UPSTREAM BIO INC

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

About GPAT GP-ACT III ACQUISITION CORP

GP-Act III Acquisition Corp is a blank check company.

Share on Social Networks: